BackGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Overview

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Inventory

Track Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's inventory ($12B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$12.21B
↑ 10.20% YoYΔ $1.13B vs prior year quarter

Peer trimmed avg / median

Loading

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Inventory History

Loading

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited vs. peers: Inventory Comparison

Loading

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SS) FAQ

As of the most recent data (September 2026), 600332.SS shows a inventory of $12B. That compares with $11B in the prior-year period — up 10.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 600332.SS's inventory is now $12B (was $11B) — a 10.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is outperforming or lagging.

Tracking 600332.SS's inventory over time shows whether Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $12B That compares with $11B in the prior-year period — up 10.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this inventory page, Stockcircle has Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect inventory (currently $12B) with ownership activity and broader fundamentals.